Comprehensive analysis of tissue samples is crucial to accurately diagnose cancer and choose the optimal treatment plan. With the rise of precision oncology, genomic profiling is playing an increasingly large role in diagnosis and clinical decision-making. Pathologists often need to answer many questions from a single sample as quickly as possible.
Why choose the Oncomap test?
This test uses next-generation sequencing (NGS) and a broad array of tumor-specific immunohistochemical (IHC) panels and single stains to identify clinically relevant genomic alterations from patient specimens as small as 3 mm2 of tissue with ≥15% tumor content,* about the size of a grain of rice. It provides this information within 7 days,*† usually before the next follow-up visit.
The test can be performed on FFPE samples, including:
- Recent and archival tissue
- Core biopsies
- Fine needle aspirate cell blocks
- Body fluid cell blocks
- Bone metastases‡
Timely results for deliberate treatment decisions
The Oncomap test can provide in-depth insights into alterations of hundreds of cancer-related genes, usually before the patient’s next follow-up visit.
Results reported within 7 days*†
-
257 genes (SNVs, CNVs, fusions, and structural variants)
-
IO signatures, including TMB and MSI
-
24 IHC stains, including PD-L1 (SP142, 22C3)
100+ therapies
45+ combination therapies
650+ clinical trials
-
>99% sensitivity and specificity,§ even on small samples
-
Compatible with fine needle aspirates and core biopsies
-
FFPE samples as small as 3 mm2 with ≥15% tumor content,* about the size of a grain of rice
Leverage NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®),1 CAP‖, and ASCO¶ recommendations to help guide evidence-based, genome-informed therapy selection and clinical trials that match your patient’s needs.
Reports to help take immediate action
Results are provided in an easy-to-interpret report with therapy options based on current NCCN Guidelines® for treatment by cancer type.1 The report also includes potential evidence-based therapies and clinical trials, delivering treatment options for a breadth of solid tumor types.
Is your patient eligible?
The Oncomap test is for patients who have advanced, metastatic, refractory, relapsed, or recurrent cancer.
Guidance for sample submission
The Oncomap test can be run on samples as small as 3 mm2 with ≥15% tumor content, but larger samples ≥10 mm2) with higher tumor content (≥20%) are preferred, when available. For tissue blocks where the overall tumor content does not meet criteria, microdissection will be performed, if possible.
To reduce delays in testing and subsequent treatment, we recommend that a pathologist select the optimal block for testing. Please reference our sample submission guidelines and choose the FFPE block with the greatest amount/area of the highest-grade carcinoma, morphologically consistent with the submitting diagnosis. Ethylenediaminetetraacetic acid (EDTA) should be used for samples requiring decalcification to preserve nucleic acid and protein expression.
-
References
Coverage and financial assistance
Exact Sciences is committed to supporting patient access to the Oncomap test to help your patients make informed decisions about their treatment.**